Powder: -20°C for 3 years | In solvent: -80°C for 1 year
I-BRD9 (GSK602) is the first selective cellular inhibitor for BRD9 with pIC50 of 7.3.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 34.00 | |
2 mg | In stock | $ 47.00 | |
5 mg | In stock | $ 68.00 | |
10 mg | In stock | $ 115.00 | |
25 mg | In stock | $ 227.00 | |
50 mg | In stock | $ 433.00 | |
100 mg | In stock | $ 642.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 76.00 |
Description | I-BRD9 (GSK602) is the first selective cellular inhibitor for BRD9 with pIC50 of 7.3. |
Targets&IC50 | BRD9:7.3 (pIC50) |
In vitro | I-BRD9 is identified through structure-based design, leading to greater than 700-fold selectivity over the BET family and 200-fold over the highly homologous bromodomain-containing protein 7 (BRD7). I-BRD9 is used to identify genes regulated by BRD9 in Kasumi-1 cells involved in oncology and immune response pathways and to the best of our knowledge, represents the first selective tool compound available to elucidate the cellular phenotype of BRD9 bromodomain inhibition[1]. |
Kinase Assay | Receptor binding is performed using membranes prepared from cells with recombinant expression of adenosine receptors as follows: human A2A and HEK 293, rat A2A and Chinese hamster ovary, human and rat A1 and Chinese hamster ovary, and human A3 and HEK 293. Radioligand competition binding assays are performed in 96-well plates in a total assay volume of 200 μL using a final test drug concentration range of between 0.1 and 3 μM. Membranes are diluted in assay buffer, pH 7.4 (A1 and A2A, Dulbecco's phosphate-buffered saline with 10 mM MgCl2; A3, 50 mM Tris-HCl, 120 mM NaCl, 10 mM MgCl2). To remove endogenous adenosine from the membrane preparations, 4 U/mL adenosine deaminase is added to the membranes, which are then incubated at room temperature for 15 min. Radioligand is added to a final concentration of 0.5 ([3H]SCH 58261, A2A), 1 ([3H]DPCPX, A1), or 0.25 ([125I]AB-MECA, A3) nM. Nonspecific binding is defined by adding 100 nM CGS 15923 (A2A), 100 nM NECA (A1), or 100 nM DPCPX (A3). Plates are incubated at room temperature with agitation for 1.5 h (A2A and A1) or 2 h (A3). Membranes are filtered onto Packard GF-B filter plates and washed in ice-cold assay buffer using a Brandel cell harvester to separate bound and free radioligand. The plates are dried before addition of 45 μL of Microscint 20 to each well. |
Synonyms | GSK602 |
Molecular Weight | 497.55 |
Formula | C22H22F3N3O3S2 |
CAS No. | 1714146-59-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (100.49 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
I-BRD9 1714146-59-4 Chromatin/Epigenetic Epigenetic Reader Domain cancer inhibit bromodomain-containing protein 7(BRD7) bromodomain and extra terminal domain (BET) BRD9 GSK 602 Kasumi-1 cells Inhibitor GSK-602 GSK602 probe I-BRD-9 I BRD9 immune response IBRD9 inhibitor